About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Per1tm1Brd
targeted mutation 1, Allan Bradley
MGI:2182834
Summary 5 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Per1tm1Brd/Per1tm1Brd 129S7/SvEvBrd-Per1tm1Brd Hprt1b-m2 MGI:4366734
hm2
Per1tm1Brd/Per1tm1Brd involves: 129 * 129S7/SvEvBrd MGI:4362034
cn3
Per1tm1Brd/Per1tm1Brd
Per2tm1Brd/Per2tm1.1Kry
Tg(Col1a1-cre)1Kry/0
involves: 129S7/SvEvBrd * FVB MGI:4362037
cx4
Per1tm1Brd/Per1tm1Brd
Per2tm1Brd/Per2tm1Brd
involves: 129S7/SvEvBrd MGI:4362033
cx5
Per1tm1Brd/Per1tm1Brd
Per2tm1Brd/Per2tm1Brd
involves: 129S7/SvEvBrd * C57BL/6 MGI:3522323


Genotype
MGI:4366734
hm1
Allelic
Composition
Per1tm1Brd/Per1tm1Brd
Genetic
Background
129S7/SvEvBrd-Per1tm1Brd Hprt1b-m2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Per1tm1Brd mutation (0 available); any Per1 mutation (62 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mutant females exhibit accelerated reproductive ageing, as indicated by a higher incidence of irregular oestrous cycles and a lower reproductive success at 9-12 months of age

reproductive system
• mutant females exhibit accelerated reproductive ageing, as indicated by a higher incidence of irregular oestrous cycles and a lower reproductive success at 9-12 months of age
• although middle-aged female mutants display significantly less regular 4-day estrous cycles than wild-type females, they exhibit more often 4-day cycles than prolonged cyclicity in 63% of the time during a 6-week observation period
• middle-aged female mutants are acyclic for 37% of a 6-week observation period, whereas age-matched wild-type females never show acyclicity
• unlike wild-type, middle-aged mutant females exhibit a significantly higher number of embryonic scars (implantations) in the uterus than the total number of live offspring detected at birth or at weanining, suggesting post-implantation embryo loss due to insufficient energy levels
• after two pregnancies, middle-aged female mutants display a significantly lower number of implantations than age-matched wild-type females
• primiparous (first parturition) wild-type and mutant females yield the same litter size as multiparous females; however, only 33.3% of multiparous mutant females breed successfully vs 90% of wild-type multiparous females
• both primiparous and multiparous middle-aged (9-12 months of age) mutant females exhibit a lower reproductive success (either fewer litters or smaller litter sizes) than middle-aged wild-type or young adult mutant females
• however, young adult mutant females (2-6 months of age) show the same success in fertility and fecundity as wild-type females
• middle-aged (9-12 months of age) female mutants produce significantly smaller litter sizes than young adult (2-6 months of age) wild-type or mutant females

behavior/neurological
• unlike pregnant wild-type females which show a progressive increase in food intake that correlates positively with body mass, midlle-aged mutant females increase their daily food intake by 20% up to midterm pregnancy but with no correlation to body mass
• both wild-type and mutant females increase their food intake by 67.6 and 63.3%, respectively, up to the 16th day of lactation
• unlike non-reproductive wild-type females which prefer 20% protein content, middle-aged non-reproductive mutant females do not display any preference to a certain protein content

growth/size/body
• loss of body mass after parturition is less pronounced in middle-aged mutant females than in wild-type females
• unlike lactating wild-type females, middle-aged mutant females show no significant changes in body mass over a 21-day lactation period
• middle-aged mutant females exhibit a lower body mass than wild-type females during the non-reproductive and pregnant stages but not when they are lactating
• however, young adult female mutants have the same body mass as wild-type females

homeostasis/metabolism
• similar to wild-type controls, middle-aged mutant females show an increase in average daily metabolic rate (ADMR) from the non-reproductive period to the lactation period; however, during pregnancy, the ADMR of mutant females is lower than that of wild-type females




Genotype
MGI:4362034
hm2
Allelic
Composition
Per1tm1Brd/Per1tm1Brd
Genetic
Background
involves: 129 * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Per1tm1Brd mutation (0 available); any Per1 mutation (62 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
skeleton
• beginning at 6 weeks of age bone mass is increased in the long bones and vertebrae




Genotype
MGI:4362037
cn3
Allelic
Composition
Per1tm1Brd/Per1tm1Brd
Per2tm1Brd/Per2tm1.1Kry
Tg(Col1a1-cre)1Kry/0
Genetic
Background
involves: 129S7/SvEvBrd * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Per1tm1Brd mutation (0 available); any Per1 mutation (62 available)
Per2tm1.1Kry mutation (0 available); any Per2 mutation (71 available)
Per2tm1Brd mutation (1 available); any Per2 mutation (71 available)
Tg(Col1a1-cre)1Kry mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
skeleton
• increase in all bone formation parameters




Genotype
MGI:4362033
cx4
Allelic
Composition
Per1tm1Brd/Per1tm1Brd
Per2tm1Brd/Per2tm1Brd
Genetic
Background
involves: 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Per1tm1Brd mutation (0 available); any Per1 mutation (62 available)
Per2tm1Brd mutation (1 available); any Per2 mutation (71 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
skeleton
• in culture osteoblasts grow faster
• the mitotic index of osteoblasts is increased and the cell cycle length is decreased
• basal osteoblast numbers are increased
• long term treatment with leptin increases rather than decreases osteoblast numbers
• beginning at 6 weeks of age bone mass is increased in the long bones and vertebrae
• increase in bone mass worsens with age
• long term treatment with leptin increases rather than decreases bone mass
• increase in all bone formation parameters

cellular
• in culture osteoblasts grow faster
• the mitotic index of osteoblasts is increased and the cell cycle length is decreased
• loss of circadian regulation of cell division in primary fibroblasts

hematopoietic system
• increase in the numbers of stromal and osteoblast progenitor cells

homeostasis/metabolism
• increase in total and bound levels of leptin
• however, levels of free leptin (active form) are similar to controls
• norepinephrine excretion is increased at Zeitgeber time (ZT) 22
• following wounding develop a thick layer of immature granulation tissue that was dominated by an excess of fibroblasts as well as polymorphonuclear cells

renal/urinary system
• norepinephrine excretion is increased at Zeitgeber time (ZT) 22




Genotype
MGI:3522323
cx5
Allelic
Composition
Per1tm1Brd/Per1tm1Brd
Per2tm1Brd/Per2tm1Brd
Genetic
Background
involves: 129S7/SvEvBrd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Per1tm1Brd mutation (0 available); any Per1 mutation (62 available)
Per2tm1Brd mutation (1 available); any Per2 mutation (71 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
• double homozygotes entrain to the LD cycle (12 h light/12 h dark); normal entrainment is caused by the inhibitory ("masking") effect of light on locomotor activity
• when placed in DD, double homozygotes show no circadian rhythms in locomotor activity, clock, or clock-controlled gene expression
• upon loss of rhythmicity, a light pulse fails to reestablish the circadian rhythm, indicating total absence of a functional clock





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/30/2024
MGI 6.23
The Jackson Laboratory